SCHEMBL818756

SCHEMBL818756

CC(C)(C)Cc1cc(S(=O)(=O)O)ccc1-c1ccc(S(=O)(=O)O)cc1CC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
TSHR P16473 3/20 0.39
NT5E P21589 2/20 0.39
HSD17B10 Q99714 4/20 0.39
TDP1 Q9NUW8 3/20 0.39
LMNA P02545 1/20 0.36
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
SNCA P37840 2/20 0.35
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA12 O43570 2/20 0.34
CA7 P43166 2/20 0.34
CA14 Q9ULX7 2/20 0.34
CASP6 P55212 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL658698 0.84 ALDH1A1 (0.38) ALDH1A1TSHRNT5EHSD17B10TDP1
SCHEMBL20222988 0.80 CASR (0.44) ALDH1A1TSHRHSD17B10LMNACA1
SCHEMBL777013 0.79 CA2 (0.42) ALDH1A1TSHRNT5EHSD17B10TDP1
SCHEMBL11100709 0.73 ESR1 (0.54) ALDH1A1TSHRNT5ETDP1LMNA
SCHEMBL2523959 0.72 ALDH1A1 (0.41) ALDH1A1TSHRNT5EHSD17B10TDP1
SCHEMBL28462905 0.70 SNCA (0.33) ALDH1A1TSHRNT5EHSD17B10TDP1
SCHEMBL11584444 0.70 ALDH1A1 (0.47) ALDH1A1TSHRNT5EHSD17B10TDP1
SCHEMBL11812442 0.70 ALDH1A1 (0.47) ALDH1A1TSHRNT5EHSD17B10TDP1
SCHEMBL25385935 0.69 ALDH1A1 (0.53) ALDH1A1TSHRNT5ETDP1LMNA
SCHEMBL16856695 0.69 ALDH1A1 (0.61) ALDH1A1TSHRNT5EHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598349-B2 Method for manufacturing conjugated aromatic compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-12-03 US disclosed
US-8293905-B2 Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
US-20110275859-A1 METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED 2011-11-10 US disclosed
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275859-A1 METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND C9, H1-10, CYP1A1 ALDH1A1 46/4885TSHR 185/4885NT5E 4382/4885
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP2M1 ALDH1A1 1092/4885TSHR 368/4885NT5E 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.